None listed
Conditions
Brief summary
This study aims to look at the inflammatory processes in patients with kidney disease who require haemodialysis. It has been shown that there is a pro-inflammatory process in this cohort of patients and this study intends to look at the specific mechanisms, immune cellular function and inflammatory molecules involved in this process. It also intends to look at the effect of Colchicine, an anti-inflammatory agent on the level of inflammatory molecules
Interventions
Oral Administration of 1mg Colchicine as an initial dose followed by another 0.5mg second dose one hour later. Tablet administration will be performed by healthcare personnel to confirm adherence
Sponsors
A/Prof Sanjay Patel
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients with end stage renal failure on haemodialysis
Exclusion criteria
Known hypersensitivity to colchicine Moderate hepatic dysfunction (Alanine Aminotransferase 1.5x upper limit of normal range) Thrombocytopaenia or leukopaenia Pregnant or lactating women and women at risk of pregnancy Patients taking moderate-strong CYP3A4 inhibitors Patients already taking Colchicine Those with evidence of active infection of inflammatory conditions that might be associated with markedly elevated CRP levels in the blood and those taking other anti-inflammatory therapies
Outcome results
None listed